FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT Sample Clauses

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT. This First Amendment to Exclusive License Agreement is entered into by and between The Xxxxx Xxxxxxx University (“JHU”) and Kala Pharmaceuticals, Inc., formerly known as Xxxxx NewCo, Inc, a Delaware corporation (“Kala” or “Company”).
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT. UC Agreement Control No. 0000-00-0000 This First Amendment to Exclusive License Agreement (this “Amendment”), dated as of November 4, 2005, is made by and among The Regents of the University of California, a California corporation (“The Regents”), Medivation, Inc., a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc., a Delaware corporation and subsidiary of Medivation (“MPT”).
Sample 1Sample 2
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT. UC Control No. 0000-00-0000 THIS FIRST AMENDMENT (the “Amendment”) is effective this 15th day of May 2009 (the “Effective Date”) by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (“The Regents”), a California corporation having its statewide administrative offices at 0000 Xxxxxxxx Xxxxxx, 00xx Xxxxx, Xxxxxxx, Xxxxxxxxxx 00000-0000, acting through the offices of The University of California, Los Angeles located at 00000 Xxxxxxx Xxxxxx, Xxxxx #000, Xxx Xxxxxxx, XX 00000-0000 and GEVO, INC. (“Licensee”) a Delaware corporation having a principal place of business at 000 X. Xxxxxxxx Xx. Xxxxx 000, Xxxxxxxx, XX, 00000, and amends the Exclusive License Agreement, Control No. 0000-00-0000, dated the 6th of September 2007, between The Regents and Licensee (the “Agreement”) in accordance with the terms and conditions of this Amendment.
Sample 1
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT. This First Amendment (the "First Amendment") to that certain Exclusive License Agreement of' March 22, 2006 (the "Agreement") by and between CELL CURE NEUROSCIENCES LTD., a corporation duly incorporated under the laws of' the State of' Israel, c/o Hadasit Medical Research Services and Development Ltd, Xxxxxx Xxxxxxxx, XX Xxx 00000, Xxxxxxxxx 00000, Xxxxxx ("CELLCURE") and ES CELL INTERNATIONAL PTE. LTD., a corporation duly incorporated under the laws of the Singapore, having its principal place of business at #00-00 Xxxxxx, 00 Xxxxxxxx Xxx, Xxxxxxxxx 000000 ("ESI") is made effective as of the Completion Date (as such term is defined in the Agreement).
Sample 1
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT. This First Amendment to Exclusive License Agreement (this “First Amendment”), is entered into as of June 5, 2020 (the “First Amendment Effective Date”), between the University of Massachusetts (“University”), a not-for-profit, public institution of higher education of the Commonwealth of Massachusetts, established by Chapter 75 of the Massachusetts General Laws, as represented by and solely for the benefit of its Medical School (Worcester campus), and Generation Bio Co. (“Company”), a Delaware corporation f/k/a Torus Therapeutics, Inc.
Sample 1

Related to FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

  • License Agreement The Trust shall have the non-exclusive right to use the name "Invesco" to designate any current or future series of shares only so long as Invesco Advisers, Inc. serves as investment manager or adviser to the Trust with respect to such series of shares.

  • Non-Exclusive Agreement The services of the Adviser to the Fund under this Agreement are not to be deemed exclusive, and the Adviser shall be free to render similar services or other services to others so long as its services hereunder are not impaired thereby.

  • Non-Exclusive License Grant In the event that either: (i) the making, have made or use by Merck or its Related Parties of any Cue Biologics during the term of this Agreement; or (ii) the making, having made, use, import, offer for sale and/or sale by Merck or its Related Parties of Compound or Product in the Territory would infringe a claim of an issued letters patent that Company (or its Affiliate) Controls and which patents are not covered by the grant in Section 3.1, Company hereby grants to Merck, to the extent Company is legally able to do so, a non-exclusive, sublicensable, royalty-free license in the Territory under such issued letters patent for Merck and its Related Parties to conduct such activities with respect to the Cue Biologics, Compounds and Products for all activities in the Field.

  • FIRST AMENDMENT TO LEASE This First Amendment to Lease (this “Amendment”), made as of March 16, 2006, by and between ARE-MA REGION NO. 28, LLC, a Delaware limited liability company (“Landlord”) and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

  • Exclusive Agreement; Amendment This Agreement supersedes all prior agreements or understandings among the parties with respect to its subject matter with respect thereto and cannot be changed or terminated orally.

  • Non-Exclusive License Sponsor grants Institution and Principal Investigator a royalty free non-exclusive license, with no right to sublicense, to use Trial Data for internal research or educational purposes. c.

  • Exclusive License Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell, and otherwise commercialize Licensed Product(s).

  • Termination of License Agreement Without limiting the generality of the foregoing, in the event that the License Agreement is terminated in accordance with its terms, this Agreement, including without limitation any Purchase Order(s) or Project Work Orders then-in-effect, shall automatically terminate in its entirety as of the effective date of termination of the License Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.